Skip to search formSkip to main contentSkip to account menu

Fludarabine-Cyclophosphamide Regimen

Known as: CF Regimen, FC Regimen, Flu-Cy Regimen 
A regimen consisting of fludarabine and cyclophosphamide used as initial treatment for chronic lymphocytic leukemia (CLL); also used for the… 
National Institutes of Health

Related topics

Related topics

6 relations
Chronic Lymphocytic LeukemiaCyclophosphamidePlatinol-Fluororuracil RegimenRefractory Mantle Cell Lymphoma

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Сравнительная эффективность добавления ритуксимаба в схему лечения хронического лимфоцитарного лейкоза
Background. Monoclonal antibodies are modern drugs for the treatment of chronic lymphocytic leukemia. The objective is a… 
2012
2012
[Clinical study on efficiency of fludarabine-based regimen for the patients with chronic lymphocytic leukemia].
The aim of this study was to evaluate the therapeutic effects and adverse reactions of fludarabine-based regimen for patients… 
2011
2011
The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection.
2010
2010
Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients
Therapy related myelodysplastic syndrome (t-MDS) and secondary acute myeloid leukemia (AML) are seriously late complications of… 
Review
2010
Review
2010
Ofatumumab Combined With Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Results From a Randomized, Multicenter…
Abstract Introduction Chemoimmunotherapy regimens are the treatment standard for fit patients with chronic lymphocytic leukemia… 
Review
2009
Review
2009
Фармакоэкономический обзор зарубежных исследований применения ритуксимаба при лечении хронического лимфолейкоза
This article contains data review of comparative assessment of "cost-effectiveness" rate of R-FC (rituximab, fludarabin… 
2008
2008
Frontline Therapy for Chronic Lymphocytic Leukemia: The Dilemma Continues
To the Editor: I would like to congratulate Bosch and colleagues on a well-conducted clinical investigation confirming the… 
2003
2003
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia
PurposeAmifostine is an organic thiophosphate that may selectively protect normal tissues from the toxicities of chemotherapy… 
1995
1995
Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
With the aim of increasing complete response rates and improving survival in cisplatin (CDDP)-based combinations (CDDP + 5… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)